Admedus attracts keen interest from surgeons at symposium
11, July, 2017
Professor Leon Neethling recently attended the 53rd Annual Meeting of the Japanese Society of Paediatric Cardiology and Cardiac Surgery, in Hamamatsu, where he presented at a lunch symposium to more than 180 congenital surgeons from Japan, Vietnam, Philippines, Malaysia, Taiwan and Korea about our ADAPT products as part of the 13th Japan-China-Korea Paediatric Heart Forum.
CardioCel: 8 years on and still free from calcification
23, August, 2016
CardioCel® is proving to be one of the biggest game changers in the congenital heart defect repairs and reconstructions space, offering significant long-term benefits to patients. While other tissue patches can calcify up to 18 months post implantation in paediatric patients, the latest follow up data released by Admedus shows no evidence of calcification using […]
Long-term CardioCel study shows no evidence of calcification after 8 years
22, August, 2016
Posted In: Uncategorized
Admedus Limited (ASX: AHZ) has today announced positive long-term data from its Phase II extension study for the repair of congenital heart defects in paediatrics using CardioCel. All patients continue to progress well, with no sign of calcification after 8 years or need for repeat procedures. Read the full Company announcement here.
Long-term study indicates no calcification with CardioCel after eight years
22, August, 2016
Long-term data from a Phase II extension study for the repair of congenital heart defects in paediatrics using CardioCel shows that all patients continue to progress well, with no sign of calcification or need for repeat procedures.